Healthcare entity

Retatrutide

Company

All 1 tracked stories fall under one category: market-trends. Eli Lilly and Company is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Retatrutide, all published on August 5, 2026.

Last mentioned: Aug 5, 2026

Entity pulse

Recent coverage · Retatrutide

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Retatrutide

All 1 tracked stories fall under one category: market-trends. Eli Lilly and Company is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Retatrutide, all published on August 5, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Retatrutide. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Expected FDA submission

    Lilly plans to file retatrutide for FDA approval.

  2. Early access program announced

    Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.

  3. 80-week trial results released

    Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.

Stories mentioning Retatrutide 1

Retatrutide is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.